Introduction
Anticancer treatment with the anthracycline Doxorubicin (Dox) increases significantly remission rate and survival with cancer. However, the dose-related toxic side effects of Dox remain of large concern, in particular Dox-induced cardiotoxicity (DIC) with left ventricular dysfunction and heart failure as its most severe form. Today, reduction of the cumulative dose of Dox still remains the most valid option to decrease the risk for DIC, nevertheless, 6-18% of adult cancer patients suffer from clinical or sub-clinical manifestation of heart failure within 9 years after chemotherapy. 1 Multiple mechanisms are associated with DIC, among them, decreased expression of cardiac-specific genes, disruption of Ca 2þ and iron homeostasis, and disruption of mitochondrial bioenergetics. 2 Activation of the renin angiotensin aldosterone system (RAAS) after chemotherapy 3 may contribute to cardiac ROS load and fibrosis suggesting beneficial effects of RAAS blockade. Clinical studies in adult cancer patients reported favourable effects of angiotensin converting enzyme inhibition (ACEi) and of angiotensin II receptor type 1 (AGTR1) blockade 4 and a recent but small clinical trial shows improvement in left ventricular (LV) function in breast cancer patients after mineralocorticoid receptor antagonism (MRA). 5 The advantage of ACEi as secondary prevention in paediatric cancer survivors was, however, only transient and related to blood pressureassociated reduction of LV wall stress 6 and favourable effects of RAAS blockade were reported for the mid-term as secondary prevention 7 but not for pre-emptive or primary protection. So far, very few animal studies delineated salvage pathways which can explain the protective potential of ACEi or MRA reported from clinical studies.
In this study, we compared eplerenone with enalapril for primary prevention against cardiotoxicity, which was induced by a single high dose of Dox (acute DIC) or by repeated small doses of Dox administered on a weekly basis (chronic DIC), with the latter intended to reflect the clinical setting. Primary prevention was started immediately after the first injection and continued until the end of study. Blockade of the RAAS with either drug did not prevent acute DIC. However, enalapril and eplerenone showed disparate effects in the chronic model where enalapril provided protection. This protection was associated with activation of the PI3K/AKT/mTOR pathway and with normal levels of connective tissue growth factor (CTGF), whereas exacerbation with eplerenone was associated with markedly increased aldosterone plasma levels and activation of the AGTR1/CTGF pathway.
Methods

Animals
Wild-type animals refer to male C57Bl/6J mice. Cardiomyocyte-specific deletion of the MR gene was achieved by crossing mice expressing Cre recombinase under control of the promoter of myosin light chain gene with mice expressing floxed MR allele. 8 Mice were housed under standard conditions. Animal experiments were approved by the Swiss Veterinary Office (Authorization number: VD2680b, Lausanne, Switzerland) and performed in accordance with guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes. Animals were sacrificed by cervical dislocation.
Dox and pharmacological treatments
Animals were 8-10 weeks old C57Bl/6 J male mice. Two models of DIC were tested based on previous literature. 9 In the acute DIC model, mice received a single intraperitoneal (i.p.) injection of Dox-HCl (Adriamycin, Pfizer, Zürich, Switzerland) at 15 mg/kg. Echocardiographic measurements were always obtained 5 days after injection. For serial investigation, animals were sacrificed at 2, 4, or 6 days after injection. In the chronic model, mice were administered weekly injections of Dox (4 mg/kg) for 5 weeks and primary prevention was continued until 4 weeks after the last injection. Echocardiographic measurements were obtained 9 weeks after the first injection, and animals were sacrificed thereafter. Control mice received injection of equal volume of saline (0.9% NaCl). In each model, primary prevention was established providing either enalapril or eplerenone with the first Dox injection and until the end of study. Control mice were fed a regular chow and Dox-injected animals were fed either normal chow or chow containing eplerenone (Pfizer) (200 mg/kg body weight per day). Enalapril (Actavis, Regensdorf, Switzerland) was given every other week in drinking water, at a concentration of 60 mg/mL.
Plasma aldosterone levels
Plasma aldosterone levels were measured according to standard procedure using the ALDO-RIACT RIA kit (Cisbio Bioassays, Codolet, France).
Echocardiography
Transthoracic echocardiography was performed in the Cardiovascular Assessment Facility on six to eight mice per group, using the Vevo 2100 ultrasound connected to MS400 probe (VisualSonics, Toronto, Canada) Standard views measured LV end-diastolic and end-systolic diameter (LVEDD and LVESD, respectively). LV stroke volume, ejection fraction and cardiac output were derived from enddiastolic and end-systolic LV volumes. The Doppler recorded mitral valve E-and A-wave from an LV apical four-chamber view. Tissue Doppler velocity was measured at the lateral annulus of the MV (lateral E 0 ). During echocardiography mice were exposed to mild anaesthesia with 1-1.5% Isoflurane.
Quantitative real-time PCR
Hearts were isolated and longitudinally cut into two pieces. One half was snap frozen in liquid nitrogen and kept at -80 C. Samples were then thawed and mechanically disrupted using TissueLyser (Qiagen, Hombrechtikon, Switzerland). Total RNA was extracted using QIAzol reagent (Qiagen) and 1 mg of total RNA was reverse transcribed using the ImPromII Reverse transcription kit (Promega, Dübendorf, Switzerland). qPCR was carried out using the Fast SYBR Green master mix (Applied Biosystems) and the QuantStudio 12k Flex real time PCR system from ThermoFisher (ThermoFisher, Ecublens, Switzerland). A list of primers pairs is provided in Supplementary material online, Table S1 .
Immunofluorescence and PicroSirius red staining
Paraffin-embedded heart sections (6 mm) were rehydrated and submitted to antigen retrieval using Tris-EDTA buffer, pH 9. Sections were then blocked 30 min in phosphate buffer saline containing 1.5% bovine serum albumin (PBS-BSA) and 0.2% Triton X-100. Primary antibodies antiLaminin (rabbit; 1:100; Sigma, St. Louis, Missouri, USA) were incubated overnight at 4 C and revealed after 1 h incubation at room temperature with Alexa Fluor secondary antibodies (all from ThermoFisher).
To detect 8-hydroxyguanosine (8-OHdG), cryosections obtained from heart embedded in OCT (Tissue-Tek) were fixed 15 min at room temperature in 4% paraformaldehyde. Sections were then blocked with PBS-BSA and with the streptavidin/biotin blocking kit (Vector labs, Burlingame, CA, USA) and incubated with anti-8-OHdG (goat; 1/150; Abcam, Cambridge, UK) overnight. Primary antibodies were detected using biotinylated secondary antibody and Alexa fluor streptavidin (ThermoFisher). Sections were imaged with a fluorescence microscope (AxioVision; Carl Zeiss, Inc., Oberkochen, Germany). For quantification, images were processed using the ImageJ software: after splitting channels from RGB images, a binary image was created from the red channel by applying the appropriate thresholding method. The number of particles was normalized to the total surface area and values obtained from four entire heart sections from n = 5 animals of each group were subjected to statistical analyses. To determine cardiomyocyte cell size, immunostaining with an antibody against Laminin was used to detect cellular circumferences in cross sectional areas (CSA). CSA was determined on transversally sectioned cardiomyocytes using ImageJ software with images first converted to a 16 bit format followed by background subtraction. After applying the Huang thresholding method, images were subjected to the 'open' binary operation and CSA were measured after scaling and setting minimum circularity to 0.5 as well as minimum cell size to 50 mm 2 . A minimum of 300 cells per animal (n = 5) were included for statistical analyses.
For collagen staining, paraffin-embedded heart sections were rehydrated and stained 1 h in 0.1% PicroSirius Red solution in saturated aqueous solution of picric acid. After 5 min of differentiation in acidified water, sections were washed under tap water, dehydrated, and mounted using Eukitt medium (Sigma). Collagen fibres were revealed under polarized light using differential interference contrast microscopy. For quantification, images were processed using the ImageJ software: after splitting channels from RGB images, a binary image was created from the green channel by applying the RenyiEntropy thresholding method. The measurements were normalized to the total surface area and values obtained from four entire heart sections from n = 4-5 animals of each group were subjected to statistical analyses.
Western blot
Proteins were extracted from frozen heart tissues in buffer consisting of 50 mM Tris-HCl, pH 7.5, 1% SDS, 0.1% Triton X-100, 1 mM EDTA, 1 mM DTT, supplemented with anti-phosphatase and protease inhibitor cocktail (Roche, Basel, Switzerland); 20-50 mg of proteins were resolved on SDS-PAGE and transferred to Immobilon PVDF membranes (Merck Millipore, Billerica, Massachusetts, United States). Membranes were then blocked in Tris-buffered saline containing 0.05% Tween 20 and 5% BSA for 30 min and incubated overnight at 4 C with primary antibodies against: MR (a kind gift from Dr Gomez-Sanchez 10 ), Akt (pan), P-Akt (Ser473), P-Akt (Thr308); AMPK, P-AMPK (Thr 172), PI3K, P-PI3K (p85 Tyr458), mTOR, P-mTOR (Ser 2448), S6, P-S6 (Ser240/244), 4EBP1, P-4EBP1, LC3, (all from Cell Signaling Technology Danvers, Massachusetts, United States), AGTR1 (Alomone Labs Ltd, Jerusalem, Israel), CTGF (Abcam), and a-tubulin (Sigma).
Primary antibody-antigen complexes were detected using appropriate HRP-conjugated secondary antibodies and ECL reagent (ThermoFisher), and band intensity was quantified using myImageAnalysis software (ThermoScientific). Values were normalized to the signal of a-tubulin.
Mitochondrial DNA damage
qPCR analysis of mitochondrial DNA damage has been performed using the Mouse real-time PCR mitochondrial DNA damage analysis kit, according to the manufacturer's instructions (Detroit R&D, Detroit, MI, USA). Values were normalized to the signal of the mitochondrial gene Cox2 (see Supplementary material online, Table S1 ).
Statistical analysis
Values are shown as mean ± SEM (or SD when stated) with n numbers and internal controls indicated in the figure legends. Two-way ANOVA with Multiple Comparison Test was used to assess significance of differences between experimental groups. Two-sided Student's t-test was used when only two groups were compared; P values were calculated using GraphPad Prism (GraphPad Software Inc.) with P < 0.05 considered significant.
Results
Eplerenone does not protect against acute DIC
Single injection of Dox (15 mg/kg) induced body weight loss within 1 day after injection and lethality starting with Day 5, which were not prevented by eplerenone treatment ( Figure 1A and B) . From Day 2 on, Dox and Dox þ eplerenone-treated animals showed marked cardiac atrophy, as observed with the decreased heart weight to tibia length ratio ( Figure  1C ), the macroscopic cross-section ( Figure 1D) , and decreased cardiomyocyte cell size ( Figure 1E and F) . Five days after injection, LV enddiastolic volume was smaller in mice treated with Dox or Dox þ eplerenone ( Figure 1G ) while LV ejection fraction (LVEF) was not modified ( Figure 1H ). These changes in combination with a reduction of heart rate (see Supplementary material online, Table S2 ) resulted in a drastic decrease of cardiac output in all groups with Dox treatment ( Figure 1I) . Remodelling of the LV was also associated with a decreased mitral E wave velocity in both groups (see Supplementary material online, Table S3 ). In all groups with Dox treatment, increased levels of expression of Nppb suggested increased wall stress, associated with blunted expression of the cardiac-specific genes Myh6 and Serca2, while unchanged expression of Myh7 indicated no reactivation of the foetal gene programme upon Dox treatment (see Supplementary material online, Figure S1A ).
Eplerenone increases plasma aldosterone and cardiac CTGF levels
Eplerenone attenuates cardiac fibrosis in different settings of cardiac remodelling. 11, 12 However, it did not decrease Dox-induced perivascular and interstitial fibrosis at 6 days after injection of Dox (Figure 2A and B).
Compatible with the increase of fibrosis, mRNA levels of Galectin-3 were higher in Dox-treated animals (see Supplementary material online, Figure S1B ). Plasma aldosterone level is a validated marker for both the severity of heart failure 13 and oral ingestion of eplerenone. 14 Dox induced a persistent increase of aldosterone levels already 2 days after injection, which was amplified by eplerenone treatment at Day 6 ( Figure 2C ), suggesting an increased aldosterone release secondary to MRA. Eplerenone treatment was associated with increased expression of the MR downstream targets, SGK1 and CTGF (see Supplementary material online, Figure S1C and D) and it intensified the Dox-induced increase in protein levels of AGTR1 on Day 2 ( Figure 2D and E) and of CTGF on Day 4 ( Figure 2D and F) . Altogether, these observations suggest that eplerenone synergistically amplifies Dox-induced molecular changes via sustained release of aldosterone and possible crosstalk with the angiotensin II (AngII) signalling. Linked to the regulation of organ size, signalling pathways controlling cell size (mTOR) and nutrient deprivation (AMPK and autophagy) were also impaired by Dox treatment and further aggravated by eplerenone (see Supplementary material online, Figure S2 ).
Cardiomyocyte-specific MR deletion does not protect against acute DIC
Similar to pharmacological MRA, genetic MR ablation in transgenic mice (Cre-MR Fl/Fl) did not prevent the cardiac atrophy ( Figure 3A) or the LV dysfunction ( Figure 3B and see Supplementary material online, Table S4 ) induced by Dox treatment. Moreover, Dox treatment similarly increased CTGF levels in both normal and MR-depleted hearts ( Figure  3C-E) . These data demonstrate that systemic pharmacological MRA or 
Enalapril protects against chronic Doxinduced LV dysfunction
Because the effects mediated by aldosterone likely involved crosstalk with AngII, we assessed whether combined treatment with eplerenone and the ACEi enalapril provides protection. However, neither treatment showed beneficial effects on LV function or morphology using the model of acute DIC (see Supplementary material online, Tables S5 and S6). We hypothesized that this model was associated with strong immediate toxicity that did not permit to investigate cardioprotective effects of RAAS blockade and therefore applied MRA and ACEi in a chronic model of DIC. Repetitive low-dose Dox administration induced body weight loss (see Supplementary material online, Figure S3A ) but was not associated with lethality. Similar to the acute model, chronic Dox treatment induced cardiac atrophy ( Figure  4A and B), reduced cardiomyocyte cell size ( Figure 4C and D) , decreased LV cardiac output ( Figure 4E) , and decreased mitral E-wave velocity ( Figure 4F ) without modifying LVEF ( Figure 4G and see Supplementary material online, Tables S6 and S7). Eplerenone treatment showed no protective effect against DIC. In contrast, enalapriltreated animals featured normal cardiac morphology and LV function ( Figure 4A-F) , 9 weeks after initiation of Dox treatment. 
Enalapril maintains low levels of CTGF and stimulates the PI3K/AKT/mTOR axis
Chronic Dox treatment neither increased plasma aldosterone ( Figure 5A ) nor fibrosis (see Supplementary material online, Figure S4A ). However, eplerenone treatment on top of Dox was associated with a marked increase of plasma aldosterone levels ( Figure 5A ) along with elevated levels of AGTR1 and of CTGF ( Figure 5B-D) , in analogy to our observations in the acute DIC model. In contrast, enalapril on top of Dox treatment had no detrimental effect on plasma aldosterone or cardiac CTGF levels, indicating that primary prevention with ACEi is more appropriate than MRA against Dox-induced cardiac remodelling. Nppb gene expression was increased in all Dox-treated animals (see Supplementary material online, Figure S3B ), which suggests the presence of discrete cardiac remodelling without immediate effect on LV functional parameters.
Normal cell size in enalapril-treated mice went along with increased phosphorylation of Akt on serine 473 and on threonine 308 and also increased activation of PI3K, mTOR, and S6, when compared with Doxtreated mice ( Figure 5E and F) . The rescue of cell morphology by enalapril, however, did not signal through 4EBP1 or AMPK, and was not associated with increased autophagy at this time point (see Supplementary material online, Figure S4B ). In addition, mitochondrial DNA damage was not increased in Dox-treated mice (see Supplementary material online, Figure S4C ). However, the proportion of cells presenting with oxidized nuclear DNA was higher in Dox-treated animals but was not different between Dox and Dox þ enalapril-treated animals (see Supplementary material online, Figure S4D ). Altogether, these data suggest that the protective effect of enalapril does not involve antioxidant properties but is mediated by activation of the PI3K/AKT/mTOR axis and by maintaining normal levels of CTGF.
Discussion
The leading cause of death in cancer survivors seems to be cardiac, 15 which emphasizes the need for pharmacological strategies offering protection against immediate and long-term cardiotoxicity. Reproducible reduction of early cardiac events, mainly of new-onset decline of LVEF was shown in clinical trials applying RAAS antagonists in pre-emptive, primary, or secondary prevention of anthracycline-induced cardiotoxicity. 4, 5, 7 This study investigated MRA and ACEi using eplerenone and enalapril, respectively, for primary prevention in mouse models of acute and chronic DIC. Both models induced marked cardiac atrophy, as reported before, [16] [17] [18] [19] and the ensuing decrease in LV volume together with reduced heart rate resulted in a decreased cardiac output that was previously described. 20, 21 The fact that LVEF remained in normal ranges after Dox treatment whereas it was decreased in identical models showing a similar decrease in heart rate and/or in LV volume 9, 17, 21 remains unclear.
We postulate that subtle differences in mouse strain and/or in Dox preparation might lead to discordant observations. In any case, we show that our protocols using Dox intended for human use, reproducibly induced cardiac dysfunction characterized by a decreased cardiac output. Neither MRA nor ACEi protected against this phenotype in the acute model, most likely related to the magnitude of toxic effects associated with a high-dose of Dox.
Pre-emptive treatment with spironolactone was associated with beneficial effects in women receiving anthracyclines for breast cancer therapy 5 and in a recent study, eplerenone showed protective effects against DIC in female mice. In this study, the Dox-induced cardiac atrophy was not associated with decreased cardiomyocyte cell size and it was not fully prevented by eplerenone; however, MRA was sufficient to prevent from Dox-induced LV dysfunction. 8 In our study, the different outcomes supporting that MRA does not protect males against DIC probably relies on gender differences, as female steroid sex hormones may control the production and action of aldosterone on cardiac tissue. 22 Accordingly, in the study from Lother et al., 8 aldosterone levels were not changed after Dox treatment while in our study, they were increased by Dox in the acute model and always increased by eplerenone treatment, as a marker of eplerenone ingestion. 14, 23 High levels of aldosterone were associated with increased levels of AGTR1 both in the acute model and in animals on eplerenone treatment in the chronic model suggesting that aldosterone promotes AGTR1 expression in an MR-independent mechanism, as reported elsewhere. 24 In the acute model, high AGTR1 levels correlated with increased CTGF levels and cardiac fibrosis, suggesting activation of the AGTR1/TGFb/CTGF pathway. 25 In the chronic model, however, high levels of CTGF were neither correlated with increased fibrosis nor with AGTR1 expression. We suggest that increased CTGF in this model results from sustained cardiac remodelling associated with multiple signalling pathways and underline that CTGF does not necessarily promote fibrosis by itself, nevertheless can cause severe cardiac damage. 26, 27 In any case, the specific role of cardiac MR remains unclear as MR deletion in cardiomyocytes does not impact on fibrosis after Dox treatment 8 and because levels of expression of MR in non-myocytes seem very low. 28 Future work will be needed to establish whether MR signalling in other cardiac cell types plays a role in DIC, as discussed especially for macrophages and endothelial cells. 8 Previous studies in rodents have suggested protective effects of ACEi against chronic DIC, 29,30 which were associated with reduced leakage of mitochondrial ROS, although the total amount of ROS were not modified by Dox. 30 In our chronic model of DIC, while mitochondrial DNA damage was not detectable, oxidative marks at the level of nuclear DNA were significantly increased by Dox treatment but were not prevented by enalapril, suggesting that enalapril did not present antioxidant properties. Enalapril treatment in the chronic model, however, was associated with protection from cardiac atrophy by stimulating mTOR pathway in the long term via increased phosphorylation of PI3K, Akt, mTOR, and S6. Cardiac atrophy was a hallmark in Dox-treated animals and was always associated with decreased cardiomyocyte cell size. Cell size is controlled by either the activity of the pro-growth PI3K/Akt/mTOR pathway or its antagonistic AMPK pathway that is activated upon energy deprivation. 31 PI3K and AKT were less activated upon Dox treatment and enalapril normalized their level of phosphorylation as well as it stimulated mTOR activity. This observation indicates a central role of mTOR in Dox-induced cardiac atrophy which corresponds to the protection from DIC using transgenic mice which overexpress constitutively active mTOR in the myocardium. 19 Rare cleaved capase-3 positive cells and unmodified total number of cardiomyocytes (data not shown) suggested that apoptosis was not the major mechanism responsible for cardiac dysfunction in our models of DIC, as suggested recently. 8 Altogether, this study highlights the role of PI3K/Akt/mTOR/S6K pathway as salvage pathway in Dox-treated mice. mTOR inhibition is relatively well-tolerated in transplant patients and have shown beneficial effects in experimental model of hypertrophy. 32 However, on the basis of the present study there is concern that inhibition of the mTOR, when used in combination with therapeutics targeting other components of the pathway, will enhance cardiotoxicity. In fact, 20% of deaths in solid-tumour patients receiving combinations of different chemotherapies together with everolimus are of cardiopulmonary origin 33 and the effect of this combination on the incidence of heart failure has not been investigated so far.
ACEi for primary prevention against cardiotoxicity 
Conclusion
In summary, our study reveals disparate effect of RAAS blockade mediated by ACEi or MRA. In particular, it brings concern about the use of eplerenone as primary prevention in cancer therapy, as MRA in male mice did not protect against DIC and was associated with high cardiac CTGF and plasma aldosterone levels. ACEi with enalapril, however, preserved cardiac morphology and function in a clinically relevant model of DIC. Protection was associated with activation of the PI3K/AKT/mTOR pathway indicating its critical role in DIC. The results of the present study provide reason to further explore the potential therapeutic implications associated with activation of this salvage pathway. In addition, the results argument for ACEi as primary prevention with prolongation of this drug treatment after the end of anticancer treatment.
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